The clinical pharmacology of eplerenone

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 4, 2009, Pages 425-432

  Muldowney III, James A S ^a,b   Schoenhard, John A ^a   Benge, Cassandra D ^b,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

Author keywords

Aldosterone; Clinical trial; Eplerenone; Heart failure; Hypertension; Mineralocorticoid receptor; Pharmacokinetics; Pharmacology

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CYTOCHROME P450 3A4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HYDROCHLOROTHIAZIDE; LOSARTAN; MINERALOCORTICOID RECEPTOR; PLACEBO; POTASSIUM; SPIRONOLACTONE;

ABDOMINAL PAIN; ADD ON THERAPY; ALBUMINURIA; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MONITORING; CHEMISTRY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; FATIGUE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; MONOTHERAPY; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PROTEINURIA; REVIEW; SIDE EFFECT; SYSTOLIC HEART FAILURE; TREATMENT DURATION; TREATMENT RESPONSE;

ALDOSTERONE ANTAGONISTS; ANIMALS; CONTROLLED CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; HYPERKALEMIA; SPIRONOLACTONE;

EID: 67649265335     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902837973     Document Type: Review

References (57)

1. Delyani JA, Rocha R, Cook CS, et al. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev 2001 Fall;19(3):185-200
2. de Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240(2):650-656 (Pubitemid 17018455)
3. de Gasparo M, Whitebread SE, Preiswerk G, et al. Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 1989;32(1B):223-227 (Pubitemid 19031486)
4. Delyani J, Myles K, Funder J. Eplerenone (SC 66110), a highly selective aldosterone antagonist. Am J Hypertens 1998;11:94A
5. Pharmaceuticals P. Eplerenone Package Insert
6. Pharmaceuticals M. Spironolactone Package Insert
7. White WB, Carr AA, Krause S, et al. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003;92(1):38-42 (Pubitemid 36782306)
8. Prisant LM, Krum H, Roniker B, et al. Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? J Clin Pharmacol 2003;43(11):1203-1210
9. Ravis WR, Reid SE, Ferry J, Tolbert DS. Effect of chronic heart failure on the pharmacokinetics of eplerenone following single and multiple dosing. American Society of Clinical Pharmacologya and Therapeutics Annual Meeting. Miami, Florida; 2004
10. Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004;110(5):558-565 (Pubitemid 39031173)
11. Rousseau MF, Gurne O, Duprez D, et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 2002;40(9):1596-1601 (Pubitemid 35253637)
12. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108(15):1831-1838 (Pubitemid 37296092)
13. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348(14):1309-1321 (Pubitemid 36384098)
14. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006;70(3):536-542 (Pubitemid 44141580)
15. Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diab Care 2005;28(9):2106-2112 (Pubitemid 41242452)
16. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15(8):709-716 (Pubitemid 34804277)
17. Sawathiparnich P, Murphey LJ, Kumar S, et al. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. J Clin Endocrinol Metab 2003;88(8):3867-3873 (Pubitemid 37034540)
18. van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 2006;24(11):2285-2292 (Pubitemid 44611039)
19. Shah NC, Pringle SD, Donnan PT, Struthers AD. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens 2007;25(11):2345-2351 (Pubitemid 47537930)
20. Yalcin AI, Dincer M, Aslan V, Gulbas Z. Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res 2002;25(4):260-264 (Pubitemid 44858335)
21. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76(17):1259-1265
22. Cook CS, Berry LM, Kim DH, et al. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos 2002;30(12):1344-1351 (Pubitemid 35397036)
23. Gardiner P, Schrode K, Quinlan D, et al. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol 1989;29(4):342-347 (Pubitemid 19125773)
24. Rocha R, Williams GH. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 2002;62(5):723-731 (Pubitemid 34494018)
25. Tolbert DS, Reid SE, Hutmacher MM. The pharmacokinetics of eplerenone in patients with left ventricular dysfunction/heart failure [abstract 27]. Pharmacotherapy 2002;23(10):1332
26. Cook CS, Berry LM, Bible RH, et al. Pharmacokinetics and metabolism of [14C] eplerenone after oral administration to humans. Drug Metab Dispos 2003;31(11):1448-1455 (Pubitemid 37310335)
27. Ravis WR, Reid S, Sica DA, Tolbert DS. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol 2005;45(7):810-821 (Pubitemid 40875333)
28. Tolbert DS, Reid SE, Roniker B. Pharmacokinetics of eplerenone in special populations [abstract 46]. Pharmacotherapy 2002;22(10):1332
29. Reid SE, Tolbert DS, Ferry J. The effect of age on the pharmacokinetics of eplerenone [abstract 212]. Pharmacotherapy 2003;23(10):1359
30. Tolbert DS, Reid SE, Roniker B. Pharmacokinetics of eplerenone coadministered with other medications [abstract 44]. Pharmacotherapy 2002;22(10):1331
31. Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003;41(7):1148-1155 (Pubitemid 36384902)
32. Weinberger MH, White WB, Ruilope LM, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005;150(3):426-433 (Pubitemid 41317608)
33. Williams GH, Burgess E, Kolloch RE, et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004;93(8):990-996 (Pubitemid 38479452)
34. White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41(5):1021-1026 (Pubitemid 36548598)
35. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;40(2):117-123 (Pubitemid 34840085)
36. Karagiannis A, Tziomalos K, Papageorgiou A, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 2008;9(4):509-515
37. Pitt B, Gheorghiade M, Zannad F, et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction
38. Pitt B, Ahmed A, Love TE, et al. History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension 2008;52(2):271-278
39. O'Keefe JH, Abuissa H, Pitt B. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes Metab 2008;10(6):492-497 (Pubitemid 351639092)
40. Taniguchi I, Kawai M, Date T, et al. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circ J 2006;70(8):995-1000 (Pubitemid 44161735)
41. Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002;25(6):837-842 (Pubitemid 36024638)
42. Sato MA, Schoorlemmer GH, Menani JV, et al. Recovery of high blood pressure after chronic lesions of the commissural NTS in SHR. Hypertension 2003;42(4):713-718 (Pubitemid 37237314)
43. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102(22):2700- 2706 (Pubitemid 30949246)
44. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001;37(5):1228-1233
45. Tsutamoto T, Wada A, Maeda K, et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2000;36(3):838-844 (Pubitemid 30681607)
46. Macdonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004;90(7):765-770 (Pubitemid 38813637)
47. Feola M, Menardi E, Ribichini F, et al. Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure. Med Sci Monit 2003;9(8):CR341-5 (Pubitemid 37139580)
48. Ogawa S, Takeuchi K, Mori T, et al. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Clin Exp Pharmacol Physiol 2006;33(5-6):477-479 (Pubitemid 43909334)
49. Joffe HV, Kwong RY, Gerhard-Herman MD, et al. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007;92(7):2552-2558 (Pubitemid 47037357)
50. Roongsritong C, Sutthiwan P, Bradley J, et al. Spironolactone improves diastolic function in the elderly. Clin Cardiol 2005;28(10):484-487 (Pubitemid 41434276)
51. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101(6):594-597 (Pubitemid 30094728)
52. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001;37(7):1800-1807 (Pubitemid 32499962)
53. Gao X, Peng L, Adhikari CM, et al. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail 2007;13(3):170-177 (Pubitemid 46591953)
54. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006;1(5):940-951
55. Furumatsu Y, Nagasawa Y, Tomida K, et al. Effect of renin-angiotensin- aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008;31(1):59-67 (Pubitemid 351325616)
56. Dieterich HA, Wendt C, Saborowski F. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure. Fiziol Cheloveka 2005;31(6):97-105
57. Boccanelli A, Mureddu GF, Cacciatore G, et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure AREA IN-CHF study): final results. Eur J Heart Fail 2009;11(1):68-76.